Lantern Pharma (LTRN) Competitors $3.52 -0.01 (-0.28%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.54 +0.02 (+0.43%) As of 04/15/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LTRN vs. LRMR, NGNE, SCPH, OGI, ADCT, KOD, TNXP, CGEN, NKTX, and CYBNShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Larimar Therapeutics (LRMR), Neurogene (NGNE), scPharmaceuticals (SCPH), Organigram (OGI), ADC Therapeutics (ADCT), Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Compugen (CGEN), Nkarta (NKTX), and Cybin (CYBN). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. Larimar Therapeutics Neurogene scPharmaceuticals Organigram ADC Therapeutics Kodiak Sciences Tonix Pharmaceuticals Compugen Nkarta Cybin Lantern Pharma (NASDAQ:LTRN) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Do analysts rate LTRN or LRMR? Lantern Pharma currently has a consensus price target of $25.00, indicating a potential upside of 610.23%. Larimar Therapeutics has a consensus price target of $19.63, indicating a potential upside of 943.88%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Do insiders & institutionals believe in LTRN or LRMR? 28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by company insiders. Comparatively, 3.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is LTRN or LRMR more profitable? Larimar Therapeutics' return on equity of -35.87% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -56.91% -51.17% Larimar Therapeutics N/A -35.87%-32.37% Does the media refer more to LTRN or LRMR? In the previous week, Lantern Pharma and Lantern Pharma both had 1 articles in the media. Lantern Pharma's average media sentiment score of 1.87 equaled Larimar Therapeutics'average media sentiment score. Company Overall Sentiment Lantern Pharma Very Positive Larimar Therapeutics Very Positive Which has higher earnings and valuation, LTRN or LRMR? Lantern Pharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$15.96M-$1.93-1.82Larimar TherapeuticsN/AN/A-$36.95M-$1.30-1.45 Does the MarketBeat Community believe in LTRN or LRMR? Larimar Therapeutics received 33 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 76.47% of users gave Lantern Pharma an outperform vote while only 71.88% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformLantern PharmaOutperform Votes1376.47% Underperform Votes423.53% Larimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% Which has more risk and volatility, LTRN or LRMR? Lantern Pharma has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. SummaryLarimar Therapeutics beats Lantern Pharma on 10 of the 14 factors compared between the two stocks. Remove Ads Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.96M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio-1.986.7921.7317.81Price / SalesN/A225.93379.1994.60Price / CashN/A65.6738.1534.64Price / Book0.945.866.464.00Net Income-$15.96M$141.86M$3.20B$247.23M7 Day Performance36.43%8.98%6.54%7.26%1 Month Performance-7.37%-12.65%-8.55%-6.26%1 Year Performance-41.04%-11.99%10.33%-0.18% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma2.1995 of 5 stars$3.52-0.3%$25.00+610.2%-41.0%$37.96MN/A-1.9820Positive NewsLRMRLarimar Therapeutics3.2748 of 5 stars$1.87-4.6%$19.63+949.5%-74.2%$119.73MN/A-1.6330Positive NewsNGNENeurogene2.1174 of 5 stars$7.86-10.6%$53.00+574.3%-69.7%$117.35M$925,000.00-1.8490Analyst ForecastNews CoverageGap UpHigh Trading VolumeSCPHscPharmaceuticals3.7514 of 5 stars$2.33+0.4%$14.00+500.9%-45.7%$117.16M$36.33M-1.2330Short Interest ↓Gap DownOGIOrganigram0.6704 of 5 stars$0.92-2.7%N/A-44.7%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.131 of 5 stars$1.17-1.3%$7.75+565.2%-72.6%$115.43M$70.84M-0.49310Gap DownKODKodiak Sciences3.6268 of 5 stars$2.18-7.2%$9.00+312.8%-40.3%$114.99MN/A-0.6090Short Interest ↑Gap DownTNXPTonix Pharmaceuticals2.4472 of 5 stars$17.80+13.8%$585.00+3,186.5%-96.4%$114.54M$10.09M0.0050CGENCompugen1.8915 of 5 stars$1.26-3.8%$4.00+217.5%-29.6%$112.44M$27.86M63.0070NKTXNkarta2.8405 of 5 stars$1.56-4.3%$14.86+852.4%-80.4%$110.69MN/A-0.83140Short Interest ↓Gap UpCYBNCybin1.5261 of 5 stars$5.15-9.5%$86.00+1,569.9%N/A$110.61MN/A-1.1850 Remove Ads Related Companies and Tools Related Companies LRMR Alternatives NGNE Alternatives SCPH Alternatives OGI Alternatives ADCT Alternatives KOD Alternatives TNXP Alternatives CGEN Alternatives NKTX Alternatives CYBN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LTRN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LTRN Stock Free LTRN Stock Alerts